Arcutis Biotherapeutics enters its Q2 2026 earnings call — confirmed for June 5 — with short interest running at a 30-day high and the stock down 11% over the past month, creating a pointed test of the bull thesis around Zoryve's commercial trajectory.
Short sellers have quietly added pressure over the past four weeks. Short interest has climbed to 14.3% of the free float — up roughly 6% over the past month and about 4% over the past week alone — after a step change around May 26 that pushed shares short from 16.9 million to 17.5 million. Days to cover sits at 7.3, meaning any meaningful short-covering event would take more than a week to work through. The lending market, however, is not registering alarm. Availability is abundant at around 716% — far above the tightest point of the past year — and the cost to borrow is a very modest 0.5%, even after ticking up about 11% on the week. That combination says shorts are adding but the borrow market is nowhere near stressed: this is directional positioning, not a squeeze setup.
Options positioning does nothing to contradict the cautious lean. The put/call ratio is 0.18, just a fraction above its 20-day average of 0.17 and well below last year's high of 0.42. Call demand still dominates the options book, so while shorts are building in the share-lending market, derivatives traders have not yet pivoted defensive. The ORTEX short score rose to 66.4 on June 2, the highest reading in at least the past ten sessions, reinforcing the directional short interest story without signalling an imminent extreme.
The Street broadly remains in the buy camp, but the most recent hard data point is a Needham reiteration of its Buy / $36 target from May 7 — filed the day after Q1 results landed and the stock fell 11.8% in a single session. The mean analyst price target sits at $34.63, a roughly 66% premium to the current $20.79 price. That gap has grown as the share price drifted lower. The bull case centres on Zoryve's expanding prescriber base across immune-mediated dermatological indications and the freed-up commercial capacity from the end of the Kowa collaboration. Bears point to competitive pressure from generics and recently approved alternatives, execution risk on the FDA approval calendar for psoriasis and atopic dermatitis, and a Q1 net loss of $11.3 million. Forward EPS growth expectations are explosive — the 12-month forward EPS increase ranks in the 97th percentile of the universe — but valuation multiples have compressed, with the P/E ratio down about 2.8 points over 30 days and the P/B ratio off 0.7 points.
On the ownership side, management sold shares at prices well above current levels — the CEO offloaded 3,172 shares at $23.61 on May 4, and the CFO sold on both May 4 and May 11. The amounts are small in dollar terms, but the direction is consistent. Marshall Wace, notably, added close to 2 million shares in Q1, the biggest new institutional build among the top holders, which provides some counterweight to the insider outflow narrative.
The last two earnings prints have punished the stock on the day: Q1 2026 results triggered an 11.8% drop the following session. The Q4 2025 print was gentler, with a 2.9% gain on the day that reversed into an 11.9% fall over the following five sessions. With the stock already 11% lower over the past month heading into Thursday's call, and close peers XNCR down 3.6% and AKBA down nearly 10% on the week, the sector backdrop is not offering support. The key question Thursday is whether Zoryve's commercial momentum — Arcutis published new clinical data on genital psoriasis management this week — is accelerating fast enough to close the gap between the Street's $34 target and a stock trading at $20.79.
See the live data behind this article on ORTEX.
Open ARQT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
